

Merkel Cell Carcinoma - Pipeline Review, 2019

<https://marketpublishers.com/r/MB7F7273446EEN.html>

Date: November 2019

Pages: 120

Price: US\$ 1,250.00 (Single User License)

ID: MB7F7273446EEN

Abstracts

Firstview Insight's Keratoconjunctivitis sicca (Dry Eye) - Pricing and Market Access provides country specific insights in order to estimate market potential for Keratoconjunctivitis sicca (Dry Eye) based on the pricing and reimbursement scenario and perceived value drivers in different market archetypes. It gives a detailed picture of the disease landscape and unmet needs of different stakeholders existing in the current treatment paradigm. Thus it enables to identify and leverage on the commercial opportunities spanning across different lines of therapy. The report incorporates detailed analysis of the market development drivers as well as the preventing factors. The scope of the report covers an extensive estimation pertaining to the winning essentials and participant schemes through a presentation of the segmentation of market in the Pricing & Market Access landscape.

Dry eyes or dry eye syndrome is a condition in which the eyes do not produce enough tears. An adequate and consistent layer of tears on the surface of the eye is essential to keep your eyes healthy, comfortable and well. Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. An adequate and consistent layer of tears on the surface of the eye is essential to keep your eyes healthy, comfortable and well. Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. The multi-screen modern lifestyle which includes eye strain due to more usage of the tablet, mobile, and computer screens are responsible for triggering the eye related problems. Products are categorized in the report by Liquid Drops, Gel, Liquid Wipes, Eye Ointment etc.

LIST OF PRODUCTS

Synthetic lacritin - TearSolutions

RX 10045

Ciclosporine/trehalose

Estradiol 3-phosphate controlled-release

OC-02

recombinant human lacritin

Ciclosporin (CEQUA)

Ciclosporin (RESTASIS)

Rebamipide (Mucosta)

Tavilermide

Timbetasin

Tivanisiran

TOP 1630

Zucapsaicin

Cinhyaluronate sodium

P-321

SA-001

Scope of the Report:

Market Access strategy for different payer archetypes

Segmentation and mapping of payers to different archetypes based on their specific criteria of assessment i.e. cost-effectiveness, budget impact, clinical effectiveness. This would enable designing effective market strategy for reimbursement in these markets. It also covers the reimbursement decisions and benefit ratings of competitor drugs by different health technology assessment bodies in EU5, US and Japan.

Payer Policy changes and implications

Provides an overview of the changing payer preferences, concerns and evolving requirements. Informs about the payer policies impacting the prescription and uptake of particular product. Estimates the future payer environment and drivers of change.

Innovative pricing and funding mechanisms

With increasing pressure from payers and limitations in evidence development, many innovative payment mechanisms are being introduced such as outcome based reimbursement, annuity based funding etc. This section provides examples of such innovative models and feasibility of their application in a particular disease scenario.

Disease Overview

This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines

Epidemiology

This section encompasses information on the incidence and prevalence of disease in EU5, US & Japan.

Existing and upcoming treatment landscape

Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning and regulatory milestones. It gives insight into the potential therapeutic targets for drug development.

Market Trends & Unmet needs

This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.

Major highlights of the report

Detailed analysis of existing and upcoming competitive landscape

HTA decisions and benefit ratings for :

NICE (UK)

GBA (Germany)

HAS(ASMR and SMR)(France)

AIFA (Italy)

AEMPS (Spain)

SMC (Scotland)

ICER (US)

Chuikyo (Japan)

Market archotyping and product positioning

Case studies on innovative funding models

Unmet need, major barriers and drivers across the industry:

Value story for achieving reimbursement and premium pricing in different markets

Contents

1. DISEASE OVERVIEW

- 1.1. Pathophysiology
- 1.2. Symptoms
- 1.3. Etiology
- 1.4. Diagnosis
- 1.5. Etiology
- 1.6. Treatment Algorithm
- 1.7. Treatment Options

2. FEATURED NEWS AND PRESS RELEASES, 2018-2019

3. LIST OF COMPANIES DEVELOPING MERKEL CELL CARCINOMA

4. TREATMENT ALGORITHM

5. CURRENT UNMET NEEDS

6. MARKET TRENDS

7. PIPELINE THERAPEUTICS

8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES **9. LATE STAGE PRODUCTS (PHASE III)**

9.1 XXX

- 9.1.1. Product Description
- 9.1.2. Research and Development
- 9.1.3. Product Development Activities

9.2. XXX

- 9.2.1. Product Description
 - 9.2.2. Research and Development
 - 9.2.3. Product Development Activities
- #### 10. Mid Stage Products (Phase II)

10.1 Cabozantinib

- 10.1.1. Product Description
- 10.1.2. Research and Development
- 10.1.3. Product Development Activities

- 10.2. Tavokinogene telseplasmid
 - 10.2.1. Product Description
 - 10.2.2. Research and Development
 - 10.2.3. Product Development Activities

11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)

- 11.1 Domatinostat
 - 11.1.1. Product Description
 - 11.1.2. Research and Development
 - 11.1.3. Product Development Activities
- 11.2. Merkel cell carcinoma therapies - Vironika
 - 11.2.1. Product Description
 - 11.2.2. Research and Development
 - 11.2.3. Product Development Activities

12. DRIVERS OF MERKEL CELL CARCINOMA

13. CONSTRAINTS OF MERKEL CELL CARCINOMA

14. THERAPEUTIC ASSESSMENT

- 14.1. Assessment by Route of Administration
- 14.2. Assessment by Phase & Route of Administration
- 14.3. Assessment by Molecule Type
- 14.4. Assessment by Phase & Molecule type
- 14.5. Assessment by Target
- 14.6. Assessment by Mechanism of Action

15. COLLABORATIONS AND ACQUISITIONS DETAILS

16. DORMANT PRODUCTS

17. DISCONTINUED PRODUCTS

18. MARKET TRENDS

19. MARKET OPPORTUNITY ASSESSMENT

20. UNMET NEEDS

21. SWOT ANALYSIS

22. APPENDIX

23. REPORT METHODOLOGY

24. CONSULTING SERVICES

25. DISCLAIMER

List Of Tables

LIST OF TABLES

- Table 1: Marketed Merkel Cell Carcinomadrugs, 2019
- Table 2: Sales of Marketed drugs
- Table 3: Patent expiration details – marketed drugs
- Table 4: Number of Products Under Development for Merkel Cell Carcinoma
- Table 5: Products under Development by Companies
- Table 6: Late Stage Products
- Table 7: Mid Stage Products
- Table 8: Early Stage Products
- Table 9: Pre-Clinical and Discovery Products
- Table 10: Assessment by Route of Administration
- Table 11: Assessment by Stage and Route of Administration
- Table 12: Assessment by Molecule Type
- Table 13: Assessment by Stage and Molecule Type
- Table 14: Assessment by Target
- Table 15: Assessment by Mechanism of Action
- Table 16: Dormant Products
- Table 17: Discontinued Products

List Of Figures

LIST OF FIGURES

Figure 1: Marketed and PipelineMerkel Cell Carcinoma - Pipeline Review, 2019drugs, 2019

Figure 2: Sales of Marketed drugs

Figure 3: Patent expiration details – marketed drugs

Figure 4: Number of Products Under Development for Merkel Cell Carcinoma - Pipeline Review, 2019

Figure 5: Products under Development by Companies

Figure 6: Late Stage Products

Figure 7: Mid Stage Products

Figure 8: Early Stage Products

Figure 9: Pre-Clinical and Discovery Products

Figure 10: Assessment by Route of Administration

Figure 11: Assessment by Stage and Route of Administration

Figure 12: Assessment by Molecule Type

Figure 13: Assessment by Stage and Molecule Type

Figure 14: Assessment by Target

Figure 15: Assessment by Mechanism of Action

Figure 16: Dormant Products

Figure17: Discontinued Products

I would like to order

Product name: Merkel Cell Carcinoma - Pipeline Review, 2019

Product link: <https://marketpublishers.com/r/MB7F7273446EEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MB7F7273446EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970